Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Spesolimab in fibrostenotic Crohn's disease (phase IIa, Japan)
jRCT2031210677Phase 2Suspended
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, randomised, double-blind trial in Crohn's disease comparing Spesolimab arm with Placebo arm (2 arms). Primary endpoints: Maintained Symptomatic Stenosis Response at Week 48 and Radiographic Stenosis Response at Week 48. Started Mar 2022; status: suspended.
02
Drugs
spesolimab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on jRCT2031210677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210677.